Marketing ROW rights has to be a tough proposition for Jon, similar to walking a tightrope. So Mr. Big Pharma, I’ve got this really cool drug approved by the FDA called Trifinotide that can be marketed ex-US that would be an excellent fit into your CNS portfolio. But Jon, weren’t you telling institutional investors anlso about a different drug that you described as your Crown Jewel? Can I also have some of that action? Sorry BP, the only thing on today’s menu is ex-US Trifinotide. Pay no attention to those Crown Jewels just yet.
Marketing ROW rights has to be a tough proposition for Jon,...
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$19.97 |
Change
0.070(0.35%) |
Mkt cap ! $2.552B | |||
| Open | High | Low | Value | Volume |
| $20.22 | $20.44 | $19.85 | $4.194M | 209.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2772 | $19.93 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $19.99 | 3310 | 1 |
View Market Depth
| Last trade - 16.10pm 04/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |